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The mammary gland is a dynamic organ displaying structural changes through-
out the female reproductive cycle. The gland differentiation follows defined stages 
(embryonic, prepubertal and pubertal stages, pregnancy, lactation and involution) 
connected to sexual development and reproduction. Complex two-way interactions 
between mammary epithelial cells and the surrounding stroma direct proliferation, 
duct formation, branching and terminal differentiation during these stages. The mem-
bers of the ERBB family of receptor tyrosine kinases (RTK) are involved in each of 
these processes and play distinct and complementary roles. 
Altered ERBB signaling, mostly due to over-expression and/or, to a minor extent, 
mutation of one or more of these receptors, results in aberrant cellular responses 
leading to breast cancers. Thus, the phenotype induced by altered ERBB modulation 
in breast cancer may highlight relevant aspects of the molecular mechanisms under-
lying normal breast development. 
In the last 15 years, in collaboration with other groups, we have studied the 
molecular basis of RTK modulation, and contributed to the definition of relevant 
molecular events and organelle interactions underlying ERBB1 (EGFR) and ERBB2 
internalization and trafficking (1-9). These studies brought us to approach the role of 
these events (10-18) in cancer pathogenesis and progression, and led to the identifica-
tion of a key druggable molecular target to revert the resistance to Trastuzumab (Her-
ceptin®), a humanized antibody to ERBB2, representing the front line treatment in 
ERBB2 over-expressing breast cancer (19).
In this lecture I will review the current knowledge on the role of ERBB receptors 
in normal breast development, their role in breast cancer onset and progression, and 
our recent results in the field.
References
[1] Confalonieri S, et al. , 2000 J Cell Biol. 150(4):905-912.
[2] Santolini E, et al. 2000, J Cell Biol. 151(6):1345-1352.
[3] Salcini A, et al. 2001, Nature Cell Biol. 3(8):755–60.
[4] Croce A, et al. 2004 Nature Cell Biol. 6(12):1173-1179. 
[5] Puri C, et al. , 2005 Mol Biol Cell. 16(6):2704-2718. 
[6] Sigismund S, et al. 2005 Proc Natl Acad Sci USA. 102(8):2760-2765. 
[7] Tosoni D, et al. 2005, Cell. 123(5):875-888. 
[8] Lampugnani MG, et al. 2006, J Cell Biol. 2006;174(4):593-604. 
[9] Caldieri G, 2017 Science. 356(6338):617-624. 
[10] Valabrega G, et al. 2005 Oncogene. 24(18):3002-10.
[11] Cortese K, et al. 2013 , Mol Biol Cell. 24(2):129-144. 
[12] Castagnola P, et al. 2016 Oncotarget. 7(51):85411-85429. 
[13] Bagnato P, et al. 2017 , Oncotarget. doi:10.18632/oncotarget.17686.
[14] Giorgi C, 2010 Science. 330(6008):1247-1251. 
[15] Daniele T, et al. 2104, Curr Biol. 24(4):393-403. 
[16] Missiroli S, et al. 2016 Cell Reports. 16(9):2415-2427. 
[17] Bononi A, et al. 2107, Nature. in press
[18] Jacchetti E, et al. 2017, Nature Comm. in press
[19] Gaviraghi M, et al. 2017 Submitted. 2017
